BerGenBio

Share Issue/Capital Change • Nov 21, 2023

BerGenBio ASA Mandatory notification of trade by primary insiders and close associates

BerGenBio ASA Mandatory notification of trade by primary insiders and close associates

Bergen 21 November 2023 - Reference is made to the stock exchange announcement

published by BerGenBio ASA (the "Company") on 15 June 2023 regarding the

allocation of offer shares and warrants (the "Warrants") to certain primary

insiders and close associates of primary insiders of the Company in connection

with the June 2023 rights issue completed pursuant to a resolution by the

Company's annual general meeting on 22 May 2023. Reference is further made to

the Company's stock exchange announcement published on 15 November 2023

regarding the commencement of the first exercise period for the Warrants. Each

Warrant gives the holder a right to subscribe for one new share ("New Share") in

the Company. The Warrants are listed and tradable on the Oslo Stock Exchange

until 16:30 hours (CEST) on 8 April 2024 under the ticker code "BGBIS".

Today, the Company has been informed that the following primary insiders and

close associate has exercised all their respective Warrants on 20 November 2023:

· Martin Olin (CEO): 1,000,000 Warrants, for the allocation of 1,000,000 New

Shares in the Company at a price per New Share of NOK 0.13.

· Rune Skeie (CFO): 129,595 Warrants, for the allocation of 129,595 New Shares

in the Company at a price per New Share of NOK 0.13.

· Anders Tullgren (chairman): 704,910 Warrants, for the allocation of 704,910

New Shares in the Company at a price per New Share of NOK 0.13.

· Sally Bennett (board member): 157,413 Warrants, for the allocation of

157,413 New Shares in the Company at a price per New Share of NOK 0.13.

· Debra Barker (board member): 155,513 Warrants, for the allocation of 155,513

New Shares in the Company at a price per New Share of NOK 0.13.

· Svev AS (company wholly owned by board member Sveinung Hole): 1,000,000

Warrants, for the allocation of 1,000,000 New Shares in the Company at a price

per New Share of NOK 0.13.

Please see further details about the transactions in the attached forms.

The New Shares issued upon exercise of Warrants will be listed on the Oslo Stock

Exchange under ISIN NO 001 0650013 and ticker code "BGBIO". The New Shares will

be listed as soon as the New Shares have been registered in the VPS and the

Company has published a prospectus in relation to the listing of the New Shares,

approved by the Norwegian Financial Supervisory Authority (the "NFSA").

The New Shares may not be transferred or traded before they are fully paid, and

the New Shares will, if required, be placed on a separate ISIN pending approval

and publication of the listing prospectus for the New Shares.

Subject to timely payment of the subscription price for the New Shares on 4

December 2023, the Company expects the share capital increase pertaining to the

exercise of Warrants to be registered with the Norwegian Register of Business

Enterprises on or about 6 December 2023 and that the New Shares will be

delivered to the VPS accounts of the subscribers to whom they are allocated on

or about 7 December 2023.

This information is subject to the disclosure requirements pursuant to article

19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian

Securities Trading Act.